{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:27:00Z","timestamp":1792657620339,"version":"4.5.0"},"reference-count":282,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01803","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T04:40:06Z","timestamp":1533876006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":70,"title":["Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus"],"prefix":"10.3389","volume":"9","author":[{"given":"Kuldeep","family":"Dhama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaragurubaran","family":"Karthik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Khandia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyma K.","family":"Latheef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthannan Andavar","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashpal Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya Veer Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanpen","family":"Chaicumpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"key":"B1","first-page":"471","article-title":"What you need to know about the Ebola virus","volume":"5","author":"Vogel","year":"2014","journal-title":"J Adv Pract Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3855\/jidc.6197","article-title":"Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives","volume":"9","author":"Dhama","year":"2015","journal-title":"J Infect Dev Ctries"},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/01652176.2017.1309474","article-title":"Ebola virus \u2013 epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans \u2013 an update on its 40 year\u2019s journey","volume":"37","author":"Singh","year":"2017","journal-title":"Vet Q"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/vbz.2008.0167","article-title":"Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo","volume":"9","author":"Leroy","year":"2007","journal-title":"Vector Borne Zoonotic Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1005780","DOI":"10.1371\/journal.ppat.1005780","article-title":"Ecological contexts of index cases and spill over events of different ebolaviruses","volume":"12","author":"Judson","year":"2016","journal-title":"PLoS Pathog"},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fpubh.2014.00278","article-title":"A new role for public health in bioterrorism deterrence","volume":"2","author":"Kosal","year":"2014","journal-title":"Front Public Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1159\/000438531","article-title":"Ebolavirus vaccines: progress in the fight against Ebola virus disease","volume":"37","author":"Wu","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(77)92000-1","article-title":"Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire","volume":"1","author":"Johnson","year":"1977","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0005700","DOI":"10.1371\/journal.pntd.0005700","article-title":"The natural history of acute Ebola virus disease among patients managed in five Ebola treatment units in West Africa: a retrospective cohort study","volume":"11","author":"Skrable","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0042-6822(85)90236-3","article-title":"Descriptive analysis of Ebola virus proteins","volume":"147","author":"Elliott","year":"1985","journal-title":"Virology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1128\/JVI.78.4.2131-2136.2004","article-title":"Distribution of hydrophobic, residues is crucial for the fusogenic properties of the Ebola virus GP2 fusion peptide","volume":"78","author":"Adam","year":"2004","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.3390\/v6093663","article-title":"Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names","volume":"6","author":"Kuhn","year":"2014","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1286-4579(99)00242-7","article-title":"Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic","volume":"1","author":"Morvan","year":"1999","journal-title":"Microbes Infect"},{"key":"B14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3389\/fimmu.2017.00252","article-title":"A perspective on the development of plant-made vaccines in the fight against Ebola virus","volume":"8","author":"Rosales-Mendoza","year":"2017","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1500306","article-title":"Persistence of Ebola virus in ocular fluid during convalescence. Persistence of Ebola virus in ocular fluid during","volume":"372","author":"Varkey","year":"2015","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/cid\/ciw202","article-title":"Ebola virus persistence in semen of male survivors","volume":"62","author":"Uyeki","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1753495X15597354","article-title":"Ebola viral disease and pregnancy","volume":"8","author":"Black","year":"2015","journal-title":"Obstet Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cid\/cix518","article-title":"Evidence of Ebola virus replication and high concentration in semen of a patient during recovery","volume":"65","author":"Barnes","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/cdd.2015.67","article-title":"Molecular mechanisms of Ebola virus pathogenesis: focus on cell death","volume":"22","author":"Falasca","year":"2015","journal-title":"Cell Death Differ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.virol.2017.06.002","article-title":"Ebolavirus protein VP24 interferes with innate immune responses by inhibiting interferon-\u03bb1 gene expression","volume":"509","author":"He","year":"2017","journal-title":"Virology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21010\/ajid.v10i2.2","article-title":"The strengths, weaknesses, opportunities, and threats (SWOTS) analyses of the Ebola virus \u2013 paper retracted","volume":"10","author":"Babalola","year":"2016","journal-title":"Afr J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00266","article-title":"Small animal models for evaluating filovirus countermeasures","author":"Banadyga","year":"2018","journal-title":"ACS Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/HAB-150284","article-title":"The emergence of antibody therapies for Ebola","volume":"23","author":"Hiatt","year":"2015","journal-title":"Hum Antibodies"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/13543784.2016.1240785","article-title":"Monoclonal antibodies for the treatment of Ebola virus disease","volume":"25","author":"Moekotte","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/imt-2017-0010","article-title":"The ongoing evolution of antibody-based treatments for Ebola virus infection","volume":"9","author":"Mendoza","year":"2017","journal-title":"Immunotherapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/1568026616666160829161318","article-title":"The drug targets and antiviral molecules for treatment of Ebola virus infection","volume":"17","author":"Wu","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e36192","DOI":"10.1371\/journal.pone.0036192","article-title":"Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever","volume":"7","author":"Marzi","year":"2012","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B29","doi-asserted-by":"publisher","first-page":"138ra81","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1056\/NEJMp1412166","article-title":"Ebola vaccine \u2014 an urgent international priority","volume":"371","author":"Kanapathipillai","year":"2014","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/inthealth\/ihx010","article-title":"Novel surveillance methods for the control of Ebola virus disease","volume":"9","author":"Houlihan","year":"2017","journal-title":"Int Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.2014.12867","article-title":"Evaluating novel therapies during the Ebola epidemic","volume":"312","author":"Joffe","year":"2014","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00299-016-2088-6","article-title":"Expression of an immunogenic LTB-based chimeric protein targeting Zaire ebolavirus epitopes from GP1 in plant cells","volume":"36","author":"Rios-Huerta","year":"2017","journal-title":"Plant Cell Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1186\/1471-2105-15-161","article-title":"A highly conserved WDYPKCDRA epitope in the RNA directed RNA polymerase of human coronaviruses can be used as epitope-based universal vaccine design","volume":"15","author":"Sharmin","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/AABC.S115859","article-title":"In-silico based vaccine design against Ebola virus glycoprotein","volume":"10","author":"Dash","year":"2017","journal-title":"Adv Appl Bioinform Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s13337-017-0398-0","article-title":"Recent advances in vaccine development against Ebola threat as bioweapon","volume":"28","author":"Gera","year":"2017","journal-title":"Virus disease"},{"key":"B38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.coviro.2017.03.008","article-title":"Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine","volume":"23","author":"Medaglini","year":"2017","journal-title":"Curr Opin Virol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1509773","article-title":"Molecular evidence of sexual transmission of Ebola virus","volume":"373","author":"Mate","year":"2015","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S2214-109X(16)30243-1","article-title":"Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study","volume":"5","author":"Sissoko","year":"2017","journal-title":"Lancet Glob Health"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S1473-3099(15)00416-8","article-title":"The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats","volume":"16","author":"Osterholm","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40203-015-0011-4","article-title":"Highly conserved regions in Ebola virus RNA dependent RNA polymerase may be act as a universal novel peptide vaccine target: a computational approach","volume":"3","author":"Oany","year":"2015","journal-title":"In silico Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/sji.12425","article-title":"B and T cell epitope-based peptides predicted from evolutionarily conserved and whole protein sequences of Ebola virus as vaccine targets","volume":"83","author":"Yasmin","year":"2016","journal-title":"Scand J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0162446","DOI":"10.1371\/journal.pone.0162446","article-title":"Ebolavirus glycoprotein Fc fusion protein protects guinea pigs against lethal challenge","volume":"11","author":"Konduru","year":"2016","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0005093","DOI":"10.1371\/journal.pntd.0005093","article-title":"Containing Ebola at the source with ring vaccination","volume":"10","author":"Merler","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1003258","DOI":"10.1371\/journal.ppat.1003258","article-title":"The secret life of viral entry glycoproteins: moonlighting in immune evasion","volume":"9","author":"Cook","year":"2013","journal-title":"PLoS Pathog"},{"key":"B47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12014-016-9119-8","article-title":"Development of a liquid chromatography high resolution mass spectrometry method for the quantitation of viral envelope glycoprotein in Ebola virus-like particle vaccine preparations","volume":"13","author":"Cazares","year":"2016","journal-title":"Clin Proteomics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"43339","DOI":"10.1038\/srep43339","article-title":"The final (oral Ebola) vaccine trial on captive Chimpanzees","volume":"7","author":"Walsh","year":"2017","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"20160295","DOI":"10.1098\/rstb.2016.0295","article-title":"A review of phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?","volume":"372","author":"Lambe","year":"2016","journal-title":"Phil Trans R Soc B"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.058","article-title":"Considerations for use of Ebola vaccine during an emergency response","author":"Walldorf","year":"2017","journal-title":"Vaccine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"10605","DOI":"10.1128\/JVI.00558-11","article-title":"Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses","volume":"85","author":"Blaney","year":"2011","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/S0140-6736(80)92352-1","article-title":"Inactivated vaccine for Ebola virus efficacious in guineapig model","volume":"2","author":"Lupton","year":"1980","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.1128\/JVI.76.18.9176-9185.2002","article-title":"Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells","volume":"76","author":"Rao","year":"2002","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.virusres.2015.10.021","article-title":"Recent advances in the development of vaccines for Ebola virus disease","volume":"211","author":"Ohimain","year":"2016","journal-title":"Virus Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"B57","doi-asserted-by":"crossref","first-page":"144.13","DOI":"10.4049\/jimmunol.194.Supp.144.13","article-title":"A single immunization with optimized DNA vaccines protects against lethal Ebola virus challenge in mice (VAC8P.1057)","volume":"194","author":"Patel","year":"2015","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jama.291.5.549","article-title":"Ebola vaccines tested in humans, monkeys","volume":"291","author":"Vastag","year":"2004","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1080\/21645515.2015.1039757","article-title":"Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges","volume":"11","author":"Grant-Klein","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding Ebola virus and Marburg virus wild-type glycoproteins in a phase I clinical trial","volume":"211","author":"Sarwar","year":"2015","journal-title":"J Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"S421","DOI":"10.1086\/520612","article-title":"Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents","volume":"196","author":"Warfield","year":"2007","journal-title":"J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12967-015-0593-y","article-title":"A thermostable, chromatographically purified Ebola nano-VLP vaccine","volume":"13","author":"Carra","year":"2015","journal-title":"J Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1084\/jem.20032141","article-title":"Role of natural killer cells in innate protection against lethal Ebola virus infection","volume":"200","author":"Warfield","year":"2004","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1308","DOI":"10.1128\/JVI.01308-17","article-title":"Cooperation of the Ebola virus proteins VP40 and GP1,2 with BST2 to activate NF-\u03baB independently of virus-like particle trapping","volume":"91","author":"Rizk","year":"2017","journal-title":"J Virol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1038\/emi.2017.31","article-title":"T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection","volume":"6","author":"Cooper","year":"2017","journal-title":"Emerg Microbes Infect"},{"key":"B67","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11262-017-1455-x","article-title":"Ebola and Marburg virus vaccines","volume":"53","author":"Reynolds","year":"2017","journal-title":"Virus Genes"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1128\/JVI.03361-12","article-title":"Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus","volume":"87","author":"Herbert","year":"2013","journal-title":"J Virol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.3389\/fmicb.2017.02662","article-title":"Alphavirus replicon DNA vectors expressing Ebola GP and VP40 antigens induce humoral and cellular immune responses in mice","volume":"8","author":"Ren","year":"2018","journal-title":"Front Microbiol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.0708057105","article-title":"Generation of biologically contained Ebola viruses","volume":"105","author":"Halfmann","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1128\/JVI.00074-09","article-title":"Replication-deficient ebolavirus as a vaccine candidate","volume":"83","author":"Halfmann","year":"2009","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"An Ebola whole-virus vaccine is protective in nonhuman primates","volume":"348","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"B73","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/21645515.2016.1225637","article-title":"Ebola virus: promising vaccine candidates","volume":"1","author":"Sameem","year":"2017","journal-title":"Vaccination Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/978-1-4939-3387-7_12","article-title":"Designing efficacious vesicular stomatitis virus-vectored vaccines against Ebola virus","volume":"1403","author":"Wong","year":"2016","journal-title":"Methods Mol Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3201\/eid2104.142012","article-title":"Safety of recombinant VSV\u2013Ebola virus vaccine vector in pigs","volume":"21","author":"Wit","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e1000225","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog"},{"key":"B79","doi-asserted-by":"publisher","first-page":"21674","DOI":"10.1038\/srep21674","article-title":"Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection","volume":"6","author":"Marzi","year":"2016","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.054","article-title":"Vaccines against Ebola virus","author":"Venkatraman","year":"2017","journal-title":"Vaccine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomized trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12910-016-0094-4","article-title":"Ebola vaccine development plan: ethics, concerns and proposed measures","volume":"17","author":"Folayan","year":"2016","journal-title":"BMC Med Ethics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jcv.2016.11.005","article-title":"Ebola virus disease: an update on current prevention and management strategies","volume":"86","author":"Trad","year":"2017","journal-title":"J Clin Virol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1128\/JVI.80.6.2738-2746.2006","article-title":"Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus","volume":"80","author":"Wang","year":"2006","journal-title":"J Virol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.chembiol.2016.07.019","article-title":"Chemical targeting of a G-quadruplex RNA in the Ebola virus L gene","volume":"23","author":"Wang","year":"2016","journal-title":"Cell Chem Biol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/14712598.2018.1404572","article-title":"From bench to almost bedside: the long road to a licensed Ebola virus vaccine","volume":"18","author":"Wong","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.antiviral.2017.07.009","article-title":"A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice","volume":"145","author":"Chen","year":"2017","journal-title":"Antiviral Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S435","DOI":"10.1093\/infdis\/jiv257","article-title":"Characterization of a bivalent vaccine capable of inducing protection against both Ebola and cross-clade H5N1 influenza in mice","volume":"212","author":"Wong","year":"2015","journal-title":"J Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"New Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00343-17","article-title":"Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles","volume":"91","author":"Schweneker","year":"2017","journal-title":"J Virol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1172\/JCI81532","article-title":"Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses","volume":"125","author":"Meyer","year":"2015","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo controlled, dose-finding, phase 1\/2a study","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med"},{"key":"B100","first-page":"567","article-title":"Tobacco against Ebola virus disease","volume":"72","author":"Budzianowski","year":"2015","journal-title":"Przegl Lek"},{"key":"B101","unstructured":"PhoolcharoenW Arizona State UniversityPlant-Produced Ebola Immune Complex as an Ebola Vaccine Candidate2010"},{"key":"B102","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00425-017-2689-5","article-title":"Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants","volume":"246","author":"Monreal-Escalante","year":"2017","journal-title":"Planta"},{"key":"B103","doi-asserted-by":"publisher","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4928637","article-title":"Plant-based vaccines: production and challenges","volume":"2016","author":"Laere","year":"2016","journal-title":"J Botany"},{"key":"B105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/bit.22652","article-title":"High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system","volume":"106","author":"Huang","year":"2010","journal-title":"Biotechnol Bioeng"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2051013615613272","article-title":"Plant based oral vaccines for human and animal pathogens \u2013 a new era of prophylaxis: current and future perspectives","volume":"1","author":"Dhama","year":"2013","journal-title":"J Exp Biol Agric Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170718114724","article-title":"Transient production of recombinant pharmaceutical proteins in plants: evolution and perspectives","author":"Kopertekh","year":"2017","journal-title":"Curr Med Chem"},{"key":"B108","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","article-title":"An inactivated rabies virus-based Ebola vaccine, filorab1, adjuvanted with glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge models","volume":"214","author":"Johnson","year":"2016","journal-title":"J Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine","volume":"9","author":"Blaney","year":"2013","journal-title":"PLoS Pathog"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.4161\/hv.21873","article-title":"A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from Ebola and Marburg virus challenge","volume":"8","author":"Grant-Klein","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/mt.2013.61","article-title":"Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola","volume":"21","author":"Shedlock","year":"2013","journal-title":"Mol Ther"},{"key":"B112","doi-asserted-by":"publisher","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","article-title":"Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections","volume":"23","author":"Swenson","year":"2005","journal-title":"Vaccine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J Infect Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41598-017-19041-y","article-title":"A single dose of modified vaccinia Ankara expressing Ebola virus like particles protects nonhuman primates from lethal Ebola virus challenge","volume":"8","author":"Domi","year":"2018","journal-title":"Sci Rep"},{"key":"B116","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e1275","DOI":"10.1371\/journal.pntd.0001275","article-title":"A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus","volume":"5","author":"Tsuda","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"B118","doi-asserted-by":"publisher","first-page":"S1060","DOI":"10.1093\/infdis\/jir347","article-title":"Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection","volume":"204","author":"Reynard","year":"2011","journal-title":"J Infect Dis"},{"key":"B119","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.virol.2010.01.015","article-title":"Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic","volume":"399","author":"Bukreyev","year":"2010","journal-title":"Virology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.vaccine.2010.10.024","article-title":"Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response","volume":"29","author":"DiNapoli","year":"2010","journal-title":"Vaccine"},{"key":"B121","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.coph.2016.08.016","article-title":"Antiviral therapeutics for the treatment of Ebola virus infection","volume":"30","author":"Cardile","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/1060028014561227","article-title":"Potential and emerging treatment options for Ebola virus disease","volume":"49","author":"Bishop","year":"2015","journal-title":"Ann Pharmacother"},{"key":"B125","doi-asserted-by":"publisher","first-page":"32","DOI":"10.7883\/yoken.JJID.2015.597","article-title":"Clinical presentation and care for patients with Ebola virus disease in China Ebola treatment unit, Liberia","volume":"70","author":"Shao","year":"2016","journal-title":"Jpn J Infect Dis"},{"key":"B126","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.amjmed.2015.01.035","article-title":"Ebola virus disease: a perspective for the United States","volume":"128","author":"Madariaga","year":"2015","journal-title":"Am J Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40259-013-0046-1","article-title":"Emerging targets and novel approaches to Ebola virus prophylaxis and treatment","volume":"27","author":"Choi","year":"2013","journal-title":"Bio Drugs"},{"key":"B128","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/phar.1545","article-title":"Treatment of Ebola virus disease","volume":"35","author":"Kilgore","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B129","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antiviral Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2017.03.003","article-title":"How to treat Ebola virus infections? A lesson from the field","volume":"24","author":"Duraffour","year":"2017","journal-title":"Curr Opin Virol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.bmcl.2017.04.028","article-title":"Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies","volume":"27","author":"Zhang","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e1005074","DOI":"10.1371\/journal.pcbi.1005074","article-title":"Systems biology-based investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis","volume":"12","author":"Cheng","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jmgm.2016.12.010","article-title":"Molecular modeling, simulation and docking study of Ebola virus glycoprotein","volume":"72","author":"Ahmad","year":"2016","journal-title":"J Mol Graph Model"},{"key":"B134","doi-asserted-by":"publisher","first-page":"192","DOI":"10.6026\/97320630012192","article-title":"Molecular docking based screening of compounds against VP40 from Ebola virus","volume":"12","author":"Alam El-Din","year":"2016","journal-title":"Bioinformation"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1016\/j.bmcl.2017.04.069","article-title":"Flex-nucleoside analogues \u2013 novel therapeutics against filoviruses","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1128\/JVI.02701-15","article-title":"Determination and therapeutic exploitation of Ebola virus spontaneous mutation frequency","volume":"90","author":"Alfson","year":"2015","journal-title":"J Virol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jcma.2014.11.007","article-title":"Overview of Ebola virus disease in 2014","volume":"78","author":"Tseng","year":"2015","journal-title":"J Chin Med Assoc"},{"key":"B138","unstructured":"2014"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e0166318","DOI":"10.1371\/journal.pone.0166318","article-title":"Evaluation of the activity of lamivudine and zidovudine against Ebola virus","volume":"11","author":"Cong","year":"2016","journal-title":"PLoS One"},{"key":"B140","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3201\/eid2103.141862","article-title":"Lack of effect of lamivudine on Ebola virus replication","volume":"21","author":"Hensley","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"B141","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12539-015-0125-8","article-title":"Flavonoids as multi-target inhibitors for proteins associated with Ebola virus: in silico discovery using virtual screening and molecular docking studies","volume":"8","author":"Raj","year":"2016","journal-title":"Interdiscip Sci"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2017.1260545","article-title":"The early clinical development of Ebola virus treatments","volume":"26","author":"Bradfute","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"B143","doi-asserted-by":"publisher","first-page":"218a","DOI":"10.1016\/j.bpj.2017.11.1217","article-title":"Potential disruption of Ebola virus matrix by graphene nano-sheets","volume":"114","author":"Pokhrel","year":"2018","journal-title":"Biophysical J"},{"key":"B144","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.antiviral.2017.11.016","article-title":"Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection","volume":"149","author":"Shtanko","year":"2018","journal-title":"Antiviral Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virol.2017.09.028","article-title":"Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry","volume":"513","author":"Qiu","year":"2018","journal-title":"Virology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e0005540","DOI":"10.1371\/journal.pntd.0005540","article-title":"The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection","volume":"11","author":"Nelson","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"B147","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2217\/fvl.14.109","article-title":"Therapeutics for postexposure treatment of Ebola virus infection","volume":"10","author":"Jerebtsova","year":"2015","journal-title":"Future Virol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2016.11.011","article-title":"The natural compound silvestrol is a potent inhibitor of Ebola virus replication","volume":"137","author":"Biedenkopf","year":"2017","journal-title":"Antiviral Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jpeds.2017.02.025","article-title":"Improvements in treatment of children younger than age 5 years infected with Ebola virus","volume":"185","author":"Yuan","year":"2017","journal-title":"J Pediatr"},{"key":"B150","doi-asserted-by":"publisher","first-page":"24782","DOI":"10.1038\/srep24782","article-title":"A web-based resource for designing therapeutics against Ebola virus","volume":"6","author":"Dhanda","year":"2016","journal-title":"Sci Rep"},{"key":"B151","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1128\/JVI.02021-09","article-title":"Different potential of C-type lectin-mediated entry between Marburg virus strains","volume":"84","author":"Matsuno","year":"2010","journal-title":"J Virol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"S957","DOI":"10.1093\/infdis\/jir326","article-title":"Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis","volume":"204","author":"Aleksandrowicz","year":"2011","journal-title":"J Infect Dis"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/emboj.2012.53","article-title":"Ebola virus entry requires the host-programmed recognition of an intracellular receptor","volume":"31","author":"Miller","year":"2012","journal-title":"EMBO J"},{"key":"B154","doi-asserted-by":"publisher","first-page":"8426","DOI":"10.1073\/pnas.1019030108","article-title":"T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus","volume":"108","author":"Kondratowicz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B155","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection","volume":"477","author":"C\u00f4t\u00e9","year":"2011","journal-title":"Nature"},{"key":"B156","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1126\/science.1258758","article-title":"Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment","volume":"347","author":"Sakurai","year":"2015","journal-title":"Science"},{"key":"B157","doi-asserted-by":"publisher","first-page":"190ra79","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci Transl Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/jac\/dku091","article-title":"The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry","volume":"69","author":"Gehring","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"B159","first-page":"162","article-title":"Amiodarone affects Ebola virus binding and entry into target cells","volume":"41","author":"Salata","year":"2018","journal-title":"New Microbiol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1021\/jacs.7b01683","article-title":"Multivalent glycosylated nanostructures to inhibit Ebola virus infection","volume":"139","author":"Illescas","year":"2017","journal-title":"J Am Chem Soc"},{"key":"B161","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2016","journal-title":"Antiviral Res"},{"key":"B162","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1128\/AAC.00543-16","article-title":"Large-scale screening and identification of novel Ebola virus and Mardburg virus entry inhibitors","volume":"60","author":"Anantpadma","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B163","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.antiviral.2016.01.001","article-title":"Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection","volume":"127","author":"Zhang","year":"2016","journal-title":"Antiviral Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"9932","DOI":"10.1128\/JVI.01337-15","article-title":"Inhibition of Ebola and Marburg virus entry by G protein-coupled receptor antagonists","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1128\/AAC.00307-16","article-title":"Prophylactic efficacy of quercetin 3-\u03b2-O-d-glucoside against Ebola virus infection","volume":"60","author":"Qiu","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"B166","doi-asserted-by":"publisher","first-page":"e2154","DOI":"10.1128\/mBio.02154-15","article-title":"Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies","volume":"7","author":"Bornholdt","year":"2016","journal-title":"mBio"},{"key":"B167","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1620\/tjem.237.45","article-title":"A synthetic serine protease inhibitor, nafamostat mesilate, is a drug potentially applicable to the treatment of Ebola virus disease","volume":"237","author":"Nishimura","year":"2015","journal-title":"Tohoku J Exp Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"e2168","DOI":"10.1128\/AAC.02168-16","article-title":"Chemically modified human serum albumin potently blocks entry of Ebola pseudoviruses and virus like particles","volume":"61","author":"Li","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B169","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/cid\/civ680","article-title":"The use of Ebola convalescent plasma to treat Ebola virus disease in resource constrained set-tings: a perspective from the field","volume":"62","author":"van Griensven","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B170","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.transci.2016.12.014","article-title":"Use of convalescent plasma in Ebola virus infection","volume":"56","author":"Garraud","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"B171","doi-asserted-by":"publisher","first-page":"g5539","DOI":"10.1136\/bmj.g5539","article-title":"First Ebola treatment is approved by WHO","volume":"349","author":"Gulland","year":"2014","journal-title":"British Med J"},{"key":"B172","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/vox.12376","article-title":"Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies","volume":"110","author":"Geisen","year":"2016","journal-title":"Vox Sang"},{"key":"B173","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2217\/imt.13.124","article-title":"An update on the use of antibodies against the filoviruses","volume":"5","author":"Saphire","year":"2013","journal-title":"Immunotherapy"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"B176","doi-asserted-by":"publisher","first-page":"S367","DOI":"10.1093\/infdis\/jiw333","article-title":"Passive immunotherapy: assessment of convalescent serum against Ebola virus Makona infection in nonhuman primates","volume":"214","author":"Mire","year":"2016","journal-title":"J Infect Dis"},{"key":"B177","doi-asserted-by":"crossref","first-page":"25","DOI":"10.18821\/0507-4088-2017-62-1-25-29","article-title":"An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever","volume":"62","author":"Borisevich","year":"2017","journal-title":"Vopr Virusol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1128\/JVI.02171-15","article-title":"Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses","volume":"90","author":"Holtsberg","year":"2016","journal-title":"J Virol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s11427-014-4746-7","article-title":"Fighting Ebola with ZMapp: spotlight on plant-made antibody","volume":"57","author":"Zhang","year":"2014","journal-title":"Sci China Life Sci"},{"key":"B180","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/infdis\/jiw493","article-title":"First newborn baby to receive experimental therapies survives Ebola virus disease","volume":"215","author":"Dornemann","year":"2017","journal-title":"J Infect Dis"},{"key":"B181","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/infdis\/jiw496","article-title":"Experimental therapies for Ebola virus disease: what have we learned?","volume":"215","author":"Hayden","year":"2017","journal-title":"J Infect Dis"},{"key":"B182","doi-asserted-by":"publisher","first-page":"878.e","DOI":"10.1016\/j.cell.2017.04.037","article-title":"Antibodies from a human survivor define sites of vulnerability for broad protection against Ebola viruses","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00652-17","article-title":"Novel cross-reactive monoclonal antibodies against Ebolavirus glycoproteins show protection in a murine challenge model","volume":"91","author":"Duehr","year":"2017","journal-title":"J Virol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","article-title":"Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site","volume":"15","author":"Howell","year":"2016","journal-title":"Cell Rep"},{"key":"B185","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody","volume":"76","author":"Parren","year":"2002","journal-title":"J Virol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","article-title":"Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor","volume":"454","author":"Lee","year":"2008","journal-title":"Nature"},{"key":"B188","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","article-title":"Cooperativity enables non-neutralizing antibodies to neutralize Ebolavirus","volume":"19","author":"Howell","year":"2017","journal-title":"Cell Rep"},{"key":"B189","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1126\/science.aag3267","article-title":"A \u201cTrojan horse\u201d bispecific antibody strategy for broad protection against ebolaviruses","volume":"354","author":"Wec","year":"2016","journal-title":"Science"},{"key":"B190","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbrc.2016.09.052","article-title":"Human transbodies to VP40 inhibit cellular egress of Ebola virus-like particles","volume":"479","author":"Teimoori","year":"2016","journal-title":"Biochem Bioph Res Co"},{"key":"B191","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41426-018-0031-3","article-title":"Human transbodies that interfere with the functions of Ebolavirus VP35 protein in genome replication and transcription and innate immune antagonism","volume":"7","author":"Seesuay","year":"2018","journal-title":"Emerg Microbe Infect"},{"key":"B192","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0167-5699(97)01234-6","article-title":"Superantibody activities: new players in innate and adaptive immune response","volume":"9","author":"Kohler","year":"1998","journal-title":"Immunol Today"},{"key":"B193","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/07388551.2015.1114465","article-title":"Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead","volume":"37","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2017","journal-title":"Crit Rev Biotechnol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebola virus infection","volume":"164","author":"Flyak","year":"2016","journal-title":"Cell"},{"key":"B195","doi-asserted-by":"publisher","first-page":"S410","DOI":"10.1093\/infdis\/jiv209","article-title":"Development and characterization of broadly cross-reactive monoclonal antibodies against all known Ebolavirus species","volume":"212","author":"Hernandez","year":"2015","journal-title":"J Infect Dis"},{"key":"B196","doi-asserted-by":"publisher","first-page":"20514","DOI":"10.1038\/srep20514","article-title":"Discovery of an antibody for pan-ebolavirus therapy","volume":"6","author":"Furuyama","year":"2016","journal-title":"Sci Rep"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.aad5788","article-title":"Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak","volume":"351","author":"Bornholdt","year":"2016","journal-title":"Science"},{"key":"B198","doi-asserted-by":"publisher","first-page":"25856","DOI":"10.1038\/srep25856","article-title":"Potent neutralizing monoclonal antibodies against Ebola virus infection","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"B199","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.1038\/s41598-017-08884-0","article-title":"Windows of opportunity for Ebola virus infection treatment and vaccination","volume":"7","author":"Nguyen","year":"2017","journal-title":"Sci Rep"},{"key":"B200","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/infdis\/jix644","article-title":"Intramuscular adeno-associated virus-mediated expression of monoclonal antibodies provides 100% protection against Ebola virus infection in mice","volume":"217","author":"van Lieshout","year":"2018","journal-title":"J Infect Dis"},{"key":"B201","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/nar\/gky187","article-title":"G-quadruplexes and G-quadruplex ligands: targets and tools in antiviral therapy","volume":"46","author":"Ruggiero","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B202","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"B203","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430\u2014a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J Infect Public Health"},{"key":"B204","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev-pharmtox-010716-105055","article-title":"Will there be a cure for Ebola?","volume":"57","author":"Cardile","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"e882","DOI":"10.1128\/mBio.00882-16","article-title":"Polyamines and hypusination are required for Ebolavirus gene expression and replication","volume":"7","author":"Olsen","year":"2016","journal-title":"mBio"},{"key":"B206","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.curtheres.2017.01.007","article-title":"Repurposed therapeutic agents targeting the Ebola virus: a systematic review","volume":"84","author":"Sweiti","year":"2017","journal-title":"Curr Therap Res"},{"key":"B207","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.antiviral.2014.04.014","article-title":"Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral dendritic cells","volume":"107","author":"Johnson","year":"2014","journal-title":"Antiviral Res"},{"key":"B208","doi-asserted-by":"publisher","first-page":"e0162199","DOI":"10.1371\/journal.pone.0162199","article-title":"Experimental treatment of Ebola virus disease with brincidofovir","volume":"11","author":"Dunning","year":"2016","journal-title":"PLoS One"},{"key":"B209","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1093\/infdis\/jiw241","article-title":"Alisporivir has limited antiviral effects against Ebola virus strains Makona and Mayinga","volume":"214","author":"Chiramel","year":"2016","journal-title":"J Infect Dis"},{"key":"B210","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41421-018-0034-1","article-title":"Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry","volume":"4","author":"Yang","year":"2018","journal-title":"Cell Discov"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2015.11.003","article-title":"Teicoplanin inhibits Ebola pseudovirus infection in cell culture","volume":"125","author":"Wang","year":"2016","journal-title":"Antiviral Res"},{"key":"B212","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1128\/JVI.79.2.918-926.2005","article-title":"Studies of Ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha","volume":"79","author":"Yonezawa","year":"2005","journal-title":"J Virol"},{"key":"B213","first-page":"87","article-title":"FGI-104: a broad-spectrum small molecule inhibitor of viral infection","volume":"1","author":"Kinch","year":"2009","journal-title":"Am J Transl Res"},{"key":"B214","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12688\/f1000research.5741.2","article-title":"A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. Version 2","volume":"3","author":"Ekins","year":"2014","journal-title":"F1000Res"},{"key":"B215","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect Dis"},{"key":"B216","doi-asserted-by":"publisher","first-page":"ftv032","DOI":"10.1093\/femspd\/ftv032","article-title":"Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process","volume":"73","author":"Salata","year":"2015","journal-title":"Pathog Dis"},{"key":"B217","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40249-015-0055-z","article-title":"Possible FDA-approved drugs to treat Ebola virus infection","volume":"4","author":"Yuan","year":"2015","journal-title":"Infect Dis Poverty"},{"key":"B218","doi-asserted-by":"publisher","first-page":"290ra89","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci Transl Med"},{"key":"B219","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","article-title":"A system for functional analysis of Ebola virus glycoprotein","volume":"94","author":"Takada","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B220","doi-asserted-by":"publisher","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"B221","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antiviral Res"},{"key":"B222","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.antiviral.2010.04.015","article-title":"Inhibition of heat-shock protein 90 reduces Ebola virus replication","volume":"87","author":"Smith","year":"2010","journal-title":"Antiviral Res"},{"key":"B223","doi-asserted-by":"publisher","first-page":"123ra24","DOI":"10.1126\/scitranslmed.3003500","article-title":"Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase","volume":"4","author":"Garc\u00eda","year":"2012","journal-title":"Sci Transl Med"},{"key":"B224","doi-asserted-by":"publisher","first-page":"E206","DOI":"10.3390\/v8080206","article-title":"Clomiphene and its isomers block Ebola virus particle entry and infection with similar potency: potential therapeutic implications","volume":"8","author":"Nelson","year":"2016","journal-title":"Viruses"},{"key":"B225","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg Microbes Infect"},{"key":"B226","doi-asserted-by":"publisher","first-page":"e60579","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PLoS One"},{"key":"B227","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.antiviral.2011.10.011","article-title":"Identification of an antioxidant small-molecule with broad-spectrum antiviral activity","volume":"93","author":"Panchal","year":"2012","journal-title":"Antiviral Res"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(03)15012-X","article-title":"Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa\/tissue factor: a study in rhesus monkeys","volume":"362","author":"Geisbert","year":"2003","journal-title":"Lancet"},{"key":"B229","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12985-016-0607-2","article-title":"Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry","volume":"13","author":"Hen\u00df","year":"2016","journal-title":"Virol J"},{"key":"B230","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12859-016-0941-9","article-title":"Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology","volume":"17","author":"Zhao","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"B231","doi-asserted-by":"publisher","first-page":"E1537","DOI":"10.3390\/molecules21121537","article-title":"Combating Ebola with repurposed therapeutics using the CANDO platform","volume":"21","author":"Chopra","year":"2016","journal-title":"Molecules"},{"key":"B232","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1128\/AAC.01105-15","article-title":"Addressing therapeutic options for Ebola virus infection in current and future outbreaks","volume":"59","author":"Haque","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B233","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.semarthrit.2013.01.001","article-title":"Multifaceted effects of hydroxychloroquine in human disease","volume":"43","author":"Olsen","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"B234","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1099\/jgv.0.000309","article-title":"Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection anddisease in the in vivo guinea pig model","volume":"96","author":"Dowall","year":"2015","journal-title":"J Gen Virol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3201\/eid2106.150176","article-title":"Lack of protection against Ebola virus from chloroquine in mice and hamsters","volume":"21","author":"Falzarano","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"B236","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12688\/f1000research.6085.2","article-title":"Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. Version 2","volume":"4","author":"Long","year":"2015","journal-title":"F1000Res"},{"key":"B237","doi-asserted-by":"publisher","first-page":"e0161311","DOI":"10.1371\/journal.pone.0161311","article-title":"Impact and lessons learned from mass drug administrations of malaria chemoprevention during the Ebola outbreak in Monrovia, Liberia, 2014","volume":"11","author":"Kuehne","year":"2016","journal-title":"PLoS One"},{"key":"B238","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"B239","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/S0140-6736(15)61095-9","article-title":"Favipiravir\u2013a prophylactic treatment for Ebola contacts?","volume":"385","author":"Van Herp","year":"2015","journal-title":"Lancet"},{"key":"B240","doi-asserted-by":"publisher","first-page":"e0006034","DOI":"10.1371\/journal.pntd.0006034","article-title":"QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient","volume":"11","author":"Chinello","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"B241","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"B242","doi-asserted-by":"publisher","first-page":"34","DOI":"10.12688\/f1000research.6110.1","article-title":"Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection","volume":"4","author":"Veljkovic","year":"2015","journal-title":"F1000Res"},{"key":"B243","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2741\/4627","article-title":"Ibuprofen as a template molecule for drug design against Ebola virus","volume":"23","author":"Paessler","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B244","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a Pyrollo[2,1f] [triazin-4-amino] Adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"key":"B245","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"B246","doi-asserted-by":"publisher","first-page":"e0169255","DOI":"10.1371\/journal.pone.0169255","article-title":"Interferon \u03b2-1a for the treatment of Ebola virus disease: a historically controlled, single-arm proof-of-concept trial","volume":"12","author":"Konde","year":"2017","journal-title":"PLoS One"},{"key":"B247","doi-asserted-by":"publisher","first-page":"e1711","DOI":"10.1128\/AAC.01711-17","article-title":"Efficacy of tilorone dihydrochloride against Ebola virus infection","volume":"62","author":"Ekins","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B248","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.2202","article-title":"Advanced antisense therapies for postexposure protection against lethal filovirus infections","volume":"16","author":"Warren","year":"2010","journal-title":"Nat Med"},{"key":"B249","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Post exposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"B250","doi-asserted-by":"publisher","first-page":"e2344","DOI":"10.1128\/mBio.02344-14","article-title":"A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection","volume":"6","author":"Warren","year":"2015","journal-title":"mBio"},{"key":"B251","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering drugs for the treatment of Ebola virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"key":"B252","doi-asserted-by":"publisher","first-page":"e1001997","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial","volume":"13","author":"Dunning","year":"2016","journal-title":"PLoS Med"},{"key":"B253","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates","volume":"521","author":"Thi","year":"2015","journal-title":"Nature"},{"key":"B254","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11427-014-4742-y","article-title":"Hsa-miR-1246, hsamiR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro","volume":"57","author":"Sheng","year":"2014","journal-title":"Sci China Life Sci"},{"key":"B255","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/v4112806","article-title":"Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections","volume":"4","author":"Iversen","year":"2012","journal-title":"Viruses"},{"key":"B256","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.1093\/infdis\/jiv223","article-title":"Novel small molecule entry inhibitors of Ebola virus","volume":"212","author":"Basu","year":"2015","journal-title":"J Infect Dis"},{"key":"B257","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"key":"B258","doi-asserted-by":"publisher","first-page":"24897","DOI":"10.1038\/srep24897","article-title":"Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle","volume":"6","author":"Dye","year":"2016","journal-title":"Sci Rep"},{"key":"B259","doi-asserted-by":"publisher","first-page":"8720","DOI":"10.1128\/JVI.01239-16","article-title":"An Ebola virus-like particle-based reporter system enables evaluation of antiviral drugs in vitro under non-biosafety level 4 conditions","volume":"90","author":"Li","year":"2016","journal-title":"J Virol"},{"key":"B260","doi-asserted-by":"publisher","first-page":"S911","DOI":"10.1093\/infdis\/jir343","article-title":"DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function","volume":"204","author":"Shabman","year":"2011","journal-title":"J Infect Dis"},{"key":"B261","doi-asserted-by":"publisher","first-page":"e0004364","DOI":"10.1371\/journal.pntd.0004364","article-title":"A rapid screening assay identifies monotherapy with interferon-\u00df and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus","volume":"10","author":"McCarthy","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B262","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1038\/srep06881","article-title":"Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus","volume":"4","author":"Audet","year":"2014","journal-title":"Sci Rep"},{"key":"B263","doi-asserted-by":"publisher","first-page":"33099","DOI":"10.1074\/jbc.M203775200","article-title":"Phosphorylation of VP30 impairs Ebola virus transcription","volume":"277","author":"Modrof","year":"2002","journal-title":"J Biol Chem"},{"key":"B264","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.antiviral.2009.06.001","article-title":"Development of a broad-spectrum antiviral with activity against Ebola virus","volume":"83","author":"Aman","year":"2009","journal-title":"Antiviral Res"},{"key":"B265","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00705-011-1115-8","article-title":"Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin","volume":"157","author":"Kolokoltsov","year":"2012","journal-title":"Arch Virol"},{"key":"B266","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1086\/514316","article-title":"Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model","volume":"179","author":"Huggins","year":"1999","journal-title":"J Infect Dis"},{"key":"B267","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1086\/504267","article-title":"Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference","volume":"193","author":"Geisbert","year":"2006","journal-title":"J Infect Dis"},{"key":"B268","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1128\/AAC.50.3.984-993.2006","article-title":"VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice","volume":"50","author":"Enterlein","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"B269","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3855\/jidc.7127","article-title":"Inhibition of Ebola virus by anti-Ebola miRNAs in silico","volume":"10","author":"Golkar","year":"2016","journal-title":"J Infect Dev Ctries"},{"key":"B270","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.antiviral.2018.02.003","article-title":"The molecular tweezer CLR01 inhibits Ebola and Zika virus infection","volume":"152","author":"Rocker","year":"2018","journal-title":"Antiviral Res"},{"key":"B271","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/cbdd.12870","article-title":"Ebola virus: a gap in drug design and discovery \u2013 experimental and computational perspective","volume":"89","author":"Balmith","year":"2017","journal-title":"Chem Biol Drug Des"},{"key":"B272","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/biolog-2017-0012","article-title":"Potential Ebola drug targets \u2013 filling the gap: a critical step forward towards the design and discovery of potential drugs","volume":"72","author":"Balmith","year":"2017","journal-title":"Biologia"},{"key":"B273","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules22101777","article-title":"A systematic review of computational drug discovery, development, and repurposing for Ebola virus disease treatment","volume":"22","author":"Schuler","year":"2017","journal-title":"Molecules"},{"key":"B274","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3923\/pjbs.2013.101.111","article-title":"Novel and emerging therapies safeguarding health of humans and their companion animals: a review","volume":"16","author":"Dhama","year":"2013","journal-title":"Pak J Biol Sci"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.2174\/1389200219666180129145252","article-title":"Medicinal and therapeutic potential of herbs and plant metabolites\/extracts countering viral pathogens \u2013 current knowledge and future prospects","author":"Dhama","year":"2018","journal-title":"Curr Drug Metab"},{"key":"B276","doi-asserted-by":"crossref","first-page":"207","DOI":"10.38150\/sajeb.3(5).p207-213","article-title":"Toll-like receptors: the innate immune receptors with ingenious anti-viral paradigm","volume":"3","author":"Malik","year":"2013","journal-title":"South Asian J Exp Biol"},{"key":"B277","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5582\/ddt.2014.01040","article-title":"Drug development for controlling Ebola epidemic \u2013 a race against time","volume":"8","author":"Gao","year":"2014","journal-title":"Drug Discov Ther"},{"key":"B278","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/pbi.12460","article-title":"Plant-made pharmaceuticals: from \u201cEdible Vaccines\u201d to Ebola therapeutics","volume":"13","author":"Arntzen","year":"2015","journal-title":"Plant Biotechnol"},{"key":"B279","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/pbi.12475","article-title":"Plant-produced candidate countermeasures against emerging and re-emerging infections and bioterror agents","volume":"13","author":"Streatfield","year":"2015","journal-title":"Plant Biotechnol J"},{"key":"B280","doi-asserted-by":"publisher","first-page":"28549","DOI":"10.3390\/ijms161226122","article-title":"Plants as factories for human pharmaceuticals: applications and challenges","volume":"16","author":"Yao","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B281","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1872213X10666161213162823","article-title":"Recent trends in nanotechnology-based drugs and formulations for targeted therapeutic delivery","volume":"10","author":"Iqbal","year":"2016","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"B282","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.biopha.2017.11.026","article-title":"Nanotherapeutics: an insight into healthcare and multi-dimensional applications in medical sector of the modern world","volume":"97","author":"Prasad","year":"2018","journal-title":"Biomed Pharmacother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T08:01:51Z","timestamp":1693814511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":282,"alternative-id":["10.3389\/fimmu.2018.01803"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01803","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"article-number":"1803"}}